We compared the oncologic outcomes of patients treated with bacillus Calmette-Guerin (BCG)-Tice versus BCG-Moreau for non–muscle-invasive bladder cancer using inverse-probability survival analyses and found no significant difference in recurrence- and progression-free survival between strains. However, the use of maintenance cycles was significantly associated with improved recurrence- and progression-free survival. Prospective designed trials are required to confirm these findings in light of the BCG shortage.
Comparative Effectiveness of Intravesical BCG-Tice and BCG-Moreau in Patients With Non–muscle-invasive Bladder Cancer
Soria F.;Gontero P.;
2020-01-01
Abstract
We compared the oncologic outcomes of patients treated with bacillus Calmette-Guerin (BCG)-Tice versus BCG-Moreau for non–muscle-invasive bladder cancer using inverse-probability survival analyses and found no significant difference in recurrence- and progression-free survival between strains. However, the use of maintenance cycles was significantly associated with improved recurrence- and progression-free survival. Prospective designed trials are required to confirm these findings in light of the BCG shortage.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Comparative Effectiveness of Intravesical BCG-Tice and BCG-Moreau in Patients With Non muscle-invasive Bladder Cancer.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
1.02 MB
Formato
Adobe PDF
|
1.02 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
